CN104582793A - 用拉喹莫德和氨吡啶的组合治疗多发性硬化症 - Google Patents

用拉喹莫德和氨吡啶的组合治疗多发性硬化症 Download PDF

Info

Publication number
CN104582793A
CN104582793A CN201380037036.0A CN201380037036A CN104582793A CN 104582793 A CN104582793 A CN 104582793A CN 201380037036 A CN201380037036 A CN 201380037036A CN 104582793 A CN104582793 A CN 104582793A
Authority
CN
China
Prior art keywords
fampridine
laquinimod
amount
methods
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380037036.0A
Other languages
English (en)
Chinese (zh)
Inventor
乔尔·凯
诺拉·塔西科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN104582793A publication Critical patent/CN104582793A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380037036.0A 2012-07-12 2013-07-11 用拉喹莫德和氨吡啶的组合治疗多发性硬化症 Pending CN104582793A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261670758P 2012-07-12 2012-07-12
US61/670,758 2012-07-12
PCT/US2013/050001 WO2014011827A1 (en) 2012-07-12 2013-07-11 Treatment of multiple sclerosis with combination of laquinimod and fampridine

Publications (1)

Publication Number Publication Date
CN104582793A true CN104582793A (zh) 2015-04-29

Family

ID=49914160

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380037036.0A Pending CN104582793A (zh) 2012-07-12 2013-07-11 用拉喹莫德和氨吡啶的组合治疗多发性硬化症

Country Status (17)

Country Link
US (2) US20140017226A1 (https=)
EP (1) EP2872217A4 (https=)
JP (1) JP2015522077A (https=)
KR (1) KR20150038072A (https=)
CN (1) CN104582793A (https=)
AR (1) AR091724A1 (https=)
AU (1) AU2013290181A1 (https=)
BR (1) BR112015000616A2 (https=)
CA (1) CA2873229A1 (https=)
EA (1) EA201590191A1 (https=)
HK (1) HK1209672A1 (https=)
IL (1) IL236230A0 (https=)
MX (1) MX2015000485A (https=)
PY (1) PY1330684A (https=)
TW (1) TW201408300A (https=)
UY (1) UY34896A (https=)
WO (1) WO2014011827A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183105A1 (en) * 1997-12-13 2006-08-17 Jayashree Aiyar Human brain-derived tissue-specific potassium channel
US20100061935A1 (en) * 2008-09-10 2010-03-11 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
US20110015132A1 (en) * 2008-03-19 2011-01-20 Proyecto De Biomedicina Cima, S.L. Synergistic 5'-methylthioadenosine combinations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
CA2851525A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183105A1 (en) * 1997-12-13 2006-08-17 Jayashree Aiyar Human brain-derived tissue-specific potassium channel
US20110015132A1 (en) * 2008-03-19 2011-01-20 Proyecto De Biomedicina Cima, S.L. Synergistic 5'-methylthioadenosine combinations
US20100061935A1 (en) * 2008-09-10 2010-03-11 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALAN M. PALMER: "Pharmacotherapeuetic Options for the Treatment of Multiple Sclerosis", 《CLINICAL MEDICINE INSIGHTS: THERAPEUTICS》 *
LARISSA VELEZ等: "Opisthotonic Posturing With Neuromuscular Irritability Attributable to 4-Aminopyridine Ingestion by a Healthy Pediatric Patient", 《PEDIATRICS》 *
LAURIE J BARTEN等: "New approaches in the management of multiple sclerosis", 《DRUG DESIGN, DEVELOPMENT AND THERAPY》 *
ROBERT J. LIPSY等: "Will the Newer Oral MS Agents Be Welcomed by Managed Care Organizations?", 《THE AMERICAN JOURNAL OF MANAGED CARE》 *
STEPHEN KRIEGER: "Multiple Sclerosis Therapeutic Pipeline:Opportunities and Challenges", 《MOUNT SINAI JOURNAL OF MEDICINE》 *

Also Published As

Publication number Publication date
EP2872217A4 (en) 2016-03-16
HK1209672A1 (en) 2016-04-08
UY34896A (es) 2014-02-28
WO2014011827A1 (en) 2014-01-16
US20140017226A1 (en) 2014-01-16
KR20150038072A (ko) 2015-04-08
CA2873229A1 (en) 2014-01-16
US20160235735A1 (en) 2016-08-18
AR091724A1 (es) 2015-02-25
AU2013290181A1 (en) 2015-02-26
MX2015000485A (es) 2015-04-08
BR112015000616A2 (pt) 2017-06-27
JP2015522077A (ja) 2015-08-03
EP2872217A1 (en) 2015-05-20
PY1330684A (es) 2016-06-01
EA201590191A1 (ru) 2015-06-30
IL236230A0 (en) 2015-01-29
TW201408300A (zh) 2014-03-01

Similar Documents

Publication Publication Date Title
JP6887952B2 (ja) 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
JP2017200927A (ja) ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
JP2017061482A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
US20160235735A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
JP2017222691A (ja) 多発性硬化症を治療するための高投与量ラキニモドの使用
WO2017048457A1 (en) Combination of laquinimod and pridopidine to treat multiple sclerosis
JP2016527270A (ja) ラキニモドおよびフルピルチンの組合せによる多発性硬化症の治療
HK1224600A1 (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
HK1224555A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2017501230A (ja) ラキニモドおよびテリフルノミドの組合せを用いた多発性硬化症の治療
TW201404395A (zh) 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）及醋酸格拉替雷（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之組合治療多發性硬化症
TW201404394A (zh) 以拉喹莫德（ＬＡＱＵＩＮＩＭＯＤ）及β－干擾素之組合治療多發性硬化症

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150429